Abstract:Objective: This study explored the value of circulating tumor cells (CTC) detected by chromosome 8 centromere probe in diagnosis of non-small cell lung cancer (NSCLC) as well as correlation between CTC counts and clinical pathological characteristics. Methods: We collected 136 patients with newly diagnosed NSCLC (101 males and 35 females, age ranged from 34 to 79 years), 149 patients with non-malignant pulmonary diseases (103 males and 46 females, age ranged from 24 to 80 years) and 32 healthy volunteers (5 males and 27 females, age ranged from 24 to 42 years). Detection was performed using an epithelial cell adhesion molecule-independent strategy that combined immunocytochemistry staining (ICC) of CD(45) and fluorescence in situ hybridization detection (FISH) with chromosome 8 centromere probe (CEP8). CTC was defined as 4',6-diamidino-2-phenylindole (DAPI) positive, CD(45) negative and CEP8 more than 2 positive points. Quantitative data were reported as x±s and Mann Whitney test was used to compare them. Measurement data were analyzed as contingency tables and Pearson chi-squared test was used. P values of less than 0.05 were considered statistically significant. Results: CTCs were detected in 114 patients (83.8%) with NSCLC, 35 patients (23.5%) with non-malignant pulmonary diseases (P<0.000 1) and 5 volunteers (15.6%). CTC counts in NSCLC patients were (5.98±0.64) per 3.2 ml and (0.60±0.13) per 3.2 ml (P<0.000 1). A receiver operating characteristic curve (ROC) analysis showed similar capability of CTC count, with CEA, in discriminating NSCLC and non-malignant diseases with an area under ROC curve of 0.854 (95% confidence interval: 0.808-0.900, P<0.001). Cutoff of 2 circulating tumor cells per 3.2 ml peripheral blood gave the highest Youden Index of 0.614 in diagnosis of NSCLC with sensitivity of 72.1% (98/136) and specificity of 89.3% (133/149). When patients with CTC≥2/3.2 ml peripheral blood or serum CEA≥5 ng/ml were considered as having NSCLC, sensitivity and specificity of this combined test were 87.5% (119/136) and 85.9% (128/149), with a higher Youden Index of 0.734. No correlation was observed between positive rate of CTC (rate of patients with CTC≥2/3.2 ml peripheral blood) and age, gender, smoking status, pathologic types, and clinical stages. Conclusions: CTC counts detected by CD(45)-FISH is higher in NSCLC patients than in non-malignant disease patients. CTC≥2/3.2 ml peripheral blood is valuable in discriminating NSCLC from nonmalignant diseases, which can be more accurate when combined with CEA.

Circulating Tumor Cells Were Associated with the Number of T Lymphocyte Subsets and NK Cells in Peripheral Blood in Advanced Non-Small-Cell Lung Cancer

Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry.

[The Value of Circulating Tumor Cells Detected by Chromosome Centromere Probe Identification in Diagnosis of Non-Small Cell Lung Cancer].

The Clinical Values of Circulating Tumor Cells and T Lymphocyte Subsets in Predicting a Prognosis of Lung Cancer

Relation between peripheral blood active circulating tumor cell and clinical characteristics of non-small cell lung cancer

Analysis of the prognostic role and biological characteristics of circulating tumor cell-associated white blood cell clusters in non-small cell lung cancer

Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression

Effect of Circulating Tumor Cells Combined with Negative Enrichment and CD45-FISH Identification in Diagnosis, Therapy Monitoring and Prognosis of Primary Lung Cancer

The Presence of Small-Size Circulating Tumor Cells Predicts Worse Prognosis in Non–Small Cell Lung Cancer Patients

Preliminary Investigation of the Clinical Significance of Detecting Circulating Tumor Cells Enriched from Lung Cancer Patients

Dynamic Changes of Circulating Tumor Cells During Chemotherapy As a Prognostic Factor in Patients with Advanced Lung Cancer.

Prognostic Significance of Circulating Tumor Cells in Non-Small-cell Lung Cancer Patients: a Meta-Analysis.

Circulating tumor cells ( CTCs )/circulating tumor endothelial cells ( CTECs ) and their subtypes in small cell lung cancer: Predictors for response and prognosis

The detection of circulating tumor cells indicates poor therapeutic efficacy and prognosis in patients with nonsmall cell lung cancer: A systematic review and meta‐analysis

Preliminary Investigation Of The Value Of The Change Of Circulating Tumor Cells In Predicting The Efficacy And Prognosis Against Advanced Non-Small Cell Lung Cancer

Epithelial‑mesenchymal Transition Phenotype of Circulating Tumor Cells is Associated with Distant Metastasis in Patients with NSCLC.

Prognostic value of circulating tumor cells combined with neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma

Lung Cancer Circulating Tumor Cells Isolated by the EpCAM-independent Enrichment Strategy Correlate with Cytokeratin 19-Derived CYFRA21-1 and Pathological Staging.

Morphology Classification of Circulating Tumor Cells Could Be a Predictor of Recurrent Disease in Patients with Non-Small Cell Lung Cancer after Surgery.

Analysis of Diagnostic Value of CTC and CTDNA in Early Lung Cancer

Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer